Business Review Financial review continued 2010 Financial highlights Cost of goods sold The following table sets out certain income statement data for the Cost of goods sold increased by $1m to $1,031m from $1,030m in periods indicated: 2009.
This represents 26% of revenue compared to 27% in 2009.
During 2010, the Group has continued to deliver on its efficiency 2010 2009 commitments, including the new Advanced Wound Management $ million $ million manufacturing facility in China and improved inventory management in Orthopaedics.
Other factors contributing to the movement were the Revenue i 3,962 3,772 decrease of $15m in restructuring and rationalisation expenses and Cost of goods sold ii 1,031 1,030 decrease of $12m in other acquisition related costs.
Currency had little impact on the year on year movement.
Gross profit 2.931 2,742 Further margin analysis is included within the Trading profit sections Marketing, selling and distribution 1,414 1,351 ofthe individual business segments that follow on pages 30 to 40. expenses iii Administrative expenses iv 446 513 Marketing, selling and distribution expenses These expenses increased by $63m 5% to $1,414m from $1,351m in Research and development expenses 151 155 2009.
In line with increased revenue there has been a 4% underlying Operating profit i 920 723 increase in advertising, marketing and selling costs.
Unfavourable currency movements have contributed to the remaining 1% movement.
Net interest payable 15 40 Other finance costs 10 15 Administrative expenses Administrative expenses decreased by $67m -13% to $446m from Share of results of associates 2 $513m in 2009.
The principal factors contributing to the underlying profit before taxation 895 670 movement of -14% were a $32m reduction in the amortisation and impairment charge of intangible assets, a $7m reduction in acquisition Taxation 280 198 related costs and a decrease of $5m in restructuring and rationalisation Attributable profit for the year 615 472 expenses.
This was partially offset by a 1% unfavourable movement in i Group revenue and operating profit are derived wholly from continuing operations and discussed currency.
on a segment basis on pages 30 to 40. ii I n 2010 no restructuring and rationalisation expenses and no acquisition related costs were Research and development expenses charged to cost of goods sold 2009 $15m of restructuring and rationalisation expenses and $12m of acquisition related costs.
Expenditure as a percentage of revenue decreased by 0.3% to 3.8% iii 2010 includes $3m of restructuring and rationalisation expenses.
No acquisition related costs were in2010 2009 4.1%.
The Group continues to invest in innovative charged to marketing, selling and distribution expenses in 2010.
2009 $7m of acquisition related costs and $10m of restructuring and rationalisation expenses.
technologies and products to differentiate itself from competitors.
iv 20 10 includes $12m of restructuring and rationalisation expenses and $34m relating to amortisation of acquisition intangibles and impairments 2009 $7m of acquisition related costs, Operating profit $17m of restructuring and rationalisation expenses and $66m relating to amortisation of acquisition intangibles and impairments.
Operating profit increased by $197m to $920m from $723m in 2009 comprising increases of $93m in Orthopaedics, $28m in Endoscopy Revenue and $76m in Advanced Wound Management.
Underlying revenue growth was 4%, and a further 1% Net interest payable growth was attributable to favourable currency translation.
Net interest payable reduced by $25m from $40m in 2009 to $15m Orthopaedics revenues increased by $60m 3%, of which 2% was in2010.
This is a consequence of the overall reduction of borrowings attributable to underlying growth, and 1% due to favourable currency within the Group and a reduction in the applicable interest rates.
Endoscopy revenues increased by $64m 8%, of which 7% was attributable to underlying growth, and 1% due to favourable Other finance cost currency translation.
Advanced Wound Management revenues Other finance costs in 2010 were $10m compared to $15m in 2009. increased by $66m 8%, of which 7% was attributable to underlying Thisdecrease is attributable to an increase in the expected return on growth and 1% due to favourable currency translation.
A more detailed analysis is included within the Revenue sections of Taxation the individual business segments that follow on pages 30 and 40.
The taxation charge increased by $82m to $280m from $198m in 2009.
The effective rate of tax was 31.3%, compared with 29.6% in 2009.
The tax charge was reduced by $10m in 2010 2009 $26m as a consequence of restructuring and rationalisation expenses, acquisition related costs, amortisation of acquisition intangibles and impairments.
The effective tax rate was 30.8% 2009 27.9% after adjusting for these items and the tax thereon.
